GH Research (NASDAQ:GHRS) Issues Quarterly Earnings Results

GH Research (NASDAQ:GHRS) posted its earnings results on Thursday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04), FiscalAI reports.

GH Research Stock Performance

NASDAQ GHRS traded down $0.02 during trading hours on Thursday, hitting $21.87. 125,495 shares of the company traded hands, compared to its average volume of 319,302. The business’s 50-day moving average is $16.89 and its 200-day moving average is $15.43. GH Research has a twelve month low of $9.52 and a twelve month high of $24.66. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -27.45 and a beta of 1.27.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Citizens Jmp lifted their target price on GH Research from $39.00 to $42.00 and gave the stock a “market outperform” rating in a report on Friday, March 6th. HC Wainwright lifted their target price on GH Research from $35.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Needham & Company LLC lifted their price target on GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Guggenheim set a $34.00 price target on GH Research and gave the company a “buy” rating in a research note on Tuesday, March 10th. Finally, Royal Bank Of Canada lifted their price target on GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.13.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new position in GH Research during the second quarter worth $79,000. BNP Paribas Financial Markets increased its position in GH Research by 165.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after buying an additional 10,600 shares during the period. Osaic Holdings Inc. increased its position in GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares during the period. UBS Group AG increased its position in GH Research by 11.5% during the 3rd quarter. UBS Group AG now owns 511,464 shares of the company’s stock worth $7,314,000 after buying an additional 52,882 shares during the period. Finally, Lynx1 Capital Management LP increased its position in GH Research by 27.5% during the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after buying an additional 1,854,238 shares during the period. 56.90% of the stock is owned by institutional investors and hedge funds.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.